Diabetes
| Obesity
Diabetes
Obesity
Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects
book_2
Source:
ADA 2022 - Oral Session
calendar_today
Published on Medfyle:
June 2022
import_contacts
4
min
In this medfyle
Dapiglutide was well-tolerated, with a safety profile similar to GLP-1RAs.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a highlights summary of an oral session given at the ADA 2022 - 82nd Scientific Sessions and presented by:
Mikkel A. Agersnap, MD, PhD
Zealand Pharma
Copenhagen, Denmark
The content is produced by Infomedica, the official reporting partner of ADA 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
